Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85480 | 1.00 | MAPT (0.34) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4810028 | 0.86 | MAPT (0.38) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL4810022 | 0.86 | MAPT (0.38) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL91570 | 0.80 | — | — | |
| SCHEMBL85417 | 0.80 | MEN1 (0.37) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL14500102 | 0.79 | MAPT (0.36) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL14592460 | 0.77 | CHRNB2 (0.37) | MAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14592124 | 0.77 | CHRNB2 (0.37) | MAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14592462 | 0.76 | MAPT (0.36) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL91944 | 0.74 | MEN1 (0.37) | MAPTALDH1A1MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | MAPT 4775/4885KDM4E 983/4885ALDH1A1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.